Alpha Synuclein Antibody (Aggregate-Specific)

What it means: Target is the antigen this antibody is intended to recognize. The target on this page is Alpha Synuclein.

How to interpret here: Use Alpha Synuclein as your primary “match checkpoint.” Confirm the symbol/name aligns with the protein you need to detect, and be cautious with closely related family members or isoforms that can share epitopes. Immunogen is Mouse alpha synuclein fibrils (species: Mouse). Immunogen context helps you anticipate epitope coverage and potential cross-reactivity (e.g., conserved regions vs unique segments). Clonality is Monoclonal (clone 2F11), which supports long-term reproducibility when reordering and comparing across studies. Reactivity is listed as Human, Mouse. Choose a species match for your samples; treat unlisted species as requiring independent validation. Host is Mouse—this guides secondary antibody selection and multiplex planning. Isotype is IgG1; match this when choosing subclass-specific secondaries or isotype controls. Conjugate options include Unconjugated; ATTO 390; ATTO 488; ATTO 594; APC; Biotin; FITC; HRP; PCP; RPE. Conjugation changes detection strategy (direct vs secondary-based) and impacts panel design. Listed applications are WB, DB, IP, IHC, ICC-IF, ImmunoGold labelling. Use these as a validation scope for your workflow and sample type. Supplier notes: This antibody binds a 3-dimensional fibrillar epitope of alpha synuclein (including AA101-120, AA61-80), present in MSA (Multiple System Atrophy) aggregates in human brain samples. It does not appear to detect PD (Parkinson's disease) or PDLB (Parkinson's disease with Lewy Bodies) aggregate structures in human brain samples. It can, however, bind recombinant human PFFs and mouse PFFs.. Use these details to interpret bands/staining patterns and plan controls. Purification is Protein G Purified—purification level can influence background in sensitive assays. Concentration is 1mg/ml; treat this as formulation information and still titrate in your assay for best signal-to-background.

Why it matters for buying:

• Specificity management: Target identity and immunogen context reduce the risk of cross-reactivity and misleading bands/staining.
• Species fit: Reactivity determines whether binding is likely in your organism and matrix.
• Workflow fit: Validation in your intended applications reduces optimization burden and failed experiments.
• Reproducibility: Clone number (for monoclonals) helps you keep results comparable over time and across labs.

Practical guidance:

• Confirm the biological form: If your study depends on a specific isoform/PTM or processed form, verify the antibody’s epitope context (immunogen/notes) aligns with that form.
• Plan specificity controls: Use known positive/negative samples and, when feasible, KO/KD/overexpression controls to confirm target-specific signal.
• Titrate for your matrix: Antibody performance is condition-dependent—optimize dilution to reduce background while preserving signal.
• Choose detection format intentionally: Use unconjugated + secondary for flexibility/amplification, or direct conjugates for faster workflows and multiplexing.

What to watch out for:

• Family-member cross-reactivity: Closely related proteins can yield off-target bands or staining; interpret multi-band patterns with controls.
• Fixation/denaturation effects: Epitopes can be masked or altered across WB vs IF/IHC; validate under your exact prep conditions.
• Cross-species assumptions: Do not assume reactivity in unlisted species without testing.

What it means: Clone number identifies the specific monoclonal antibody clone. The clone listed here is 2F11.

How to interpret here: Use 2F11 as the identifier for reproducibility—clone names help you match literature, compare vendors, and reorder the same binding behavior over time. Isotype is IgG1; this matters for subclass-specific secondaries, isotype controls, and Fc-binding reagents (Protein A/G). Conjugate options include Unconjugated; ATTO 390; ATTO 488; ATTO 594; APC; Biotin; FITC; HRP; PCP; RPE. The same clone may be available in different conjugated formats; detection changes but epitope binding is typically the same. Applications listed: WB, DB, IP, IHC, ICC-IF, ImmunoGold labelling. Confirm this clone is supported for your intended method and sample prep. Supplier notes: This antibody binds a 3-dimensional fibrillar epitope of alpha synuclein (including AA101-120, AA61-80), present in MSA (Multiple System Atrophy) aggregates in human brain samples. It does not appear to detect PD (Parkinson's disease) or PDLB (Parkinson's disease with Lewy Bodies) aggregate structures in human brain samples. It can, however, bind recombinant human PFFs and mouse PFFs.—use these to interpret expected band size or specificity caveats.

Why it matters for buying:

• Reproducibility: Clone identity is the most reliable way to obtain the same monoclonal specificity.
• Panel design: In multiplex staining/flow, clone choice affects epitope competition and staining intensity.
• Continuity: Labs often standardize on clone names; matching clone reduces retraining and re-optimization.

Practical guidance:

• Document the clone: Record clone + lot + dilution in your methods to preserve reproducibility.
• Check epitope competition: For multi-antibody panels, avoid using two clones that compete for the same epitope on the same target.
• Choose conjugate to match platform: For direct detection, pick a conjugate compatible with your instrument/filters and compensation plan.

What to watch out for:

• Same target, different clones: Antibodies to the same target are not interchangeable—clone behavior can differ by application and sample prep.
• Lot effects: Monoclonals are generally consistent, but conjugation and handling can still shift performance—revalidate when switching lots for quantitative work.

What it means: Clonality describes whether the antibody comes from a single clone (monoclonal) or a mixture recognizing multiple epitopes (polyclonal). The value shown here is Monoclonal.

How to interpret here: Use Monoclonal to choose between epitope precision vs broader epitope coverage. Clonality can affect specificity, robustness across sample prep, and lot-to-lot consistency. This is a monoclonal with clone 2F11, which supports reproducibility and consistent epitope recognition. Monoclonals often provide cleaner specificity and are easier to standardize for quantitative comparisons. Applications listed: WB, DB, IP, IHC, ICC-IF, ImmunoGold labelling. If your epitope is sensitive to fixation/denaturation, polyclonals sometimes perform better; for standardized quantitation, monoclonals are often preferred. Host is Mouse—plan secondary antibodies accordingly. Reactivity is Human, Mouse; clonality does not guarantee cross-species performance—validate per species.

Why it matters for buying:

• Specificity vs sensitivity: Monoclonals favor specificity; polyclonals may increase sensitivity/robustness.
• Reproducibility: Clone-defined reagents simplify long-term consistency and cross-lab comparisons.
• Assay dependence: Some assays tolerate multi-epitope binding better than others (e.g., IHC/IF vs quantitative WB).

Practical guidance:

• If you need consistency: Prefer monoclonal + clone number, and record lot information for publications.
• If signal is difficult: Consider whether multi-epitope recognition (polyclonal) could help under your prep conditions.
• Validate with controls: Use KO/KD, peptide blocking (when appropriate), or orthogonal methods to support specificity claims.

What to watch out for:

• Transfer across applications: An antibody’s clonality does not guarantee performance in every application—optimize for your method.
• Polyclonal lot variation: Revalidate when switching lots if your experiment depends on quantitative consistency.

What it means: Application(s) lists methods the supplier indicates this antibody has been used for. The value shown here is WB, DB, IP, IHC, ICC-IF, ImmunoGold labelling.

How to interpret here: Use WB, DB, IP, IHC, ICC-IF, ImmunoGold labelling as the closest available “validation scope” for your workflow. Performance is still dependent on sample type, prep conditions, and antigen abundance. Target is Alpha Synuclein—plan positive/negative controls that match expected expression and localization. Reactivity is Human, Mouse—validation may not transfer across species without testing. Clonality is Monoclonal; this can influence robustness across fixation/denaturation conditions. Conjugate options include Unconjugated; ATTO 390; ATTO 488; ATTO 594; APC; Biotin; FITC; HRP; PCP; RPE; direct conjugates can simplify IF/FC workflows, while unconjugated formats provide flexibility. Supplier notes: This antibody binds a 3-dimensional fibrillar epitope of alpha synuclein (including AA101-120, AA61-80), present in MSA (Multiple System Atrophy) aggregates in human brain samples. It does not appear to detect PD (Parkinson's disease) or PDLB (Parkinson's disease with Lewy Bodies) aggregate structures in human brain samples. It can, however, bind recombinant human PFFs and mouse PFFs.—use these to interpret expected band sizes or specificity caveats in your readout.

Why it matters for buying:

• Risk reduction: Choosing an antibody already used in your application lowers the chance of extensive troubleshooting.
• Protocol compatibility: Some methods (IHC/IF/FC) are more sensitive to background than WB—validation matters more.
• Budget efficiency: Selecting the right format up-front (unconjugated vs conjugated) avoids re-purchasing.

Practical guidance:

• WB: Confirm expected molecular weight/isoforms; interpret multi-band patterns with controls (KO/KD when feasible).
• IHC: Fixation and antigen retrieval strongly affect staining; include isotype and secondary-only controls.
• IP: Binding can be buffer-dependent; use lysis conditions that preserve epitope/complex and confirm pull-down by WB or MS.
• Record conditions: Document dilution, buffer, and sample prep for reproducibility and future reorders.

What to watch out for:

• Application transfer risk: Validation in one method doesn’t guarantee success in another.
• Matrix effects: Tissue autofluorescence, Fc receptor binding, and endogenous Ig can elevate background—controls matter.
• Lot changes: Revalidate after switching lots for critical quantitative comparisons.

What it means: Host is the species the antibody was raised in. The value shown here is Mouse.

How to interpret here: Use Mouse to select compatible secondary antibodies/detection reagents and to plan background controls. Use anti-mouse secondary reagents (and consider mouse-on-mouse background in mouse tissues). Isotype is IgG1—match subclass-specific secondaries and isotype controls when needed. Conjugate options include Unconjugated; ATTO 390; ATTO 488; ATTO 594; APC; Biotin; FITC; HRP; PCP; RPE; direct conjugates may not require a secondary antibody. Reactivity is Human, Mouse—remember: host = antibody origin; reactivity = species where the antigen is expected to be recognized. Applications listed: WB, DB, IP, IHC, ICC-IF, ImmunoGold labelling. Host choice matters most in IF/IHC/FC where secondary-driven background can dominate.

Why it matters for buying:

• Secondary compatibility: Host determines which secondaries and detection systems you can use.
• Multiplexing: Using primaries from different hosts can simplify multi-target staining.
• Background control: Certain sample types can bind secondaries non-specifically; host choice affects how hard background is to manage.

Practical guidance:

• Use cross-adsorbed secondaries: Helps reduce cross-reactivity in complex tissues or multiplex panels.
• Include secondary-only controls: Essential for interpreting IF/IHC background.
• Block Fc receptors when relevant: Particularly in immune-rich tissues or flow cytometry.

What to watch out for:

• Mouse-on-mouse background: Mouse primaries on mouse tissues can increase background—specialized strategies may be required.
• Subclass mismatches: Subclass-specific secondaries require a matching isotype/subclass.
• Cross-reactive secondaries: Poorly adsorbed secondaries can bind other primaries—validate multiplex reagents.